460 related articles for article (PubMed ID: 26822204)
21. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
Sandborn WJ; Vermeire S; Tyrrell H; Hassanali A; Lacey S; Tole S; Tatro AR;
Adv Ther; 2020 Jul; 37(7):3417-3431. PubMed ID: 32445184
[TBL] [Abstract][Full Text] [Related]
22. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
[TBL] [Abstract][Full Text] [Related]
23. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Panés J; Salas A
J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
25. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T; Fedyk E; Abhyankar B
J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
[TBL] [Abstract][Full Text] [Related]
26. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Scribano ML
World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
[TBL] [Abstract][Full Text] [Related]
27. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
28. Integrin antagonists are effective and safe for Crohn's disease: a meta-analysis.
Ge WS; Fan JG
World J Gastroenterol; 2015 Apr; 21(15):4744-9. PubMed ID: 25914486
[TBL] [Abstract][Full Text] [Related]
29. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
30. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
32. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
33. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
Domènech E; Gisbert JP
Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
[TBL] [Abstract][Full Text] [Related]
35. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
D'Amico F; Fiorino G; Peyrin-Biroulet L; Danese S
Immunotherapy; 2019 May; 11(7):565-575. PubMed ID: 30860423
[TBL] [Abstract][Full Text] [Related]
36. Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents.
Solitano V; Parigi TL; Ragaini E; Danese S
Expert Opin Investig Drugs; 2021 Oct; 30(10):1037-1046. PubMed ID: 34449288
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
[TBL] [Abstract][Full Text] [Related]
38. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.
McLean LP; Shea-Donohue T; Cross RK
Immunotherapy; 2012 Sep; 4(9):883-98. PubMed ID: 23046232
[TBL] [Abstract][Full Text] [Related]
39. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
40. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
